Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | Parmaneti | GNG Pharma | Akhali Khedva | Iberi + | Iberiparma + |
|---|---|---|---|---|---|
| Total Revenue | 6,688 | 6,249 | — | — | — |
| Total COGS | -5,471 | -4,011 | — | — | — |
| Gross Profit | 1,217 | 2,238 | — | — | — |
| Gross Margin | 18.2% | 35.8% | — | — | — |
| Total Operating Expenses | -833 | -1,980 | — | — | — |
| EBITDA | 384 | 258 | — | — | — |
| EBITDA Margin | 5.7% | 4.1% | — | — | — |
| Total D&A | -36 | -46 | — | — | — |
| EBIT / Operating Income | 348 | 211 | — | — | — |
| Total Interest Expense | -65 | — | — | — | — |
| Total Other Income | -31 | -159 | — | — | — |
| Profit Before Tax | 253 | 53 | — | — | — |
| Total Income Tax | 0 | -25 | — | — | — |
| Net Profit / (Loss) | 253 | 28 | — | — | — |
| Net Margin | 3.8% | 0.5% | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Parmaneti | Pharma | 5.7% | 25th pct | 110 |
| GNG Pharma | Pharma | 4.1% | 20th pct | 110 |
| Akhali Khedva | Pharma | — | no FY data | 110 |
| Iberi + | Pharma | — | no FY data | 110 |
| Iberiparma + | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.